FibroBiologics closes $3M public offering of common stock and warrants at $1.32/unit

FibroBiologics, Inc.

Offering of 2,272,728 shares (or pre-funded warrants) plus warrants, combined price $1.32/unit; net proceeds ~$2.5M after fees.
Warrants exercise price $1.32, exercisable only after stockholder approval; if fully cash-exercised, additional $3M proceeds possible.
Pre-funded warrants exercise price $0.00001, no expiration; beneficial ownership cap 9.99%.
Placement agent H.C. Wainwright received 7.0% cash fee, 1.0% management fee, and 159,091 placement agent warrants at $1.65.
Lock-up: insiders 30 days; company restricted from further equity issuance for 30 days and no variable-rate transactions for one year.

item 1.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

FibroBiologics, Inc. entered into Purchase Agreement with certain investors (effective 2026-03-31).

Action: entry
Agreement: equity purchase
Counterparty: certain investors
Effective: 2026-03-31

Exact text from the filing

certain of the investors purchased their Shares and Pre-Funded Warrants, together with the accompanying Warrants, pursuant to a securities purchase agreement, dated March 31, 2026, by and among the Company and such investors (the “Purchase Agreement”).

View on SEC.gov

Browse all material agreements →

FibroBiologics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-140044

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.